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Abstract
Background: Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its
incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid
(AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety
of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and
kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence
and/or severity of renal injury.
Methods: Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of
contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or
placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin
(NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of
mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by
staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA
transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2)
encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA
analysis of kidney lysates.
Results: Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3μg/mmol versus
533.6μg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:
creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In
support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml
versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated
decreased TUNEL and caspase-3 expression in both low and high dose AA groups.
Conclusions: Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further
work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular
procedures.
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Background
Contrast-induced nephropathy (CIN) is the commonest
cause of iatrogenic renal injury and its incidence is in-
creasing due to the rise in the number and complexity of
endovascular interventions [1]. This is increasingly appar-
ent with prolonged endovascular aortic interventions such
as fenestrated endovascular aortic aneurysm repair where
high intra-arterial x-ray contrast media volumes may be
administered. CIN is therefore a significant clinical prob-
lem, accounting for 10% of all hospital-acquired renal in-
sufficiency [2], and is strongly associated with adverse
clinical outcomes and prolonged hospital length of stay
[3]. The development of CIN is associated with an in-
crease in both in-hospital and 1-year mortality, irrespect-
ive of whether dialysis is necessary [4]. The quoted
incidence of renal insufficiency following open and endo-
vascular aneurysm repair (EVAR) varies widely [1, 5, 6],
and it is clear that the cause of this damage is complex
and may include aortic/stent-graft manipulation, blood
loss and anaesthetic factors as well as CIN. In spite of
these complications the patient benefit of less invasive
EVAR (compared to conventional surgery) is, however,
significant in that the risk of renal hypo perfusion second-
ary to hemodynamic instability and cross clamping is
eliminated, surgical trauma is reduced, and ischemia-
reperfusion injury is attenuated. However, EVAR still
causes a significant systemic reaction, possibly through a
combination of ischemia-reperfusion injury. Moreover,
while the contemporary literature may suggest that EVAR
protects the kidneys perioperatively, emerging data raise
the possibility that long-term renal injury may be greater
following EVAR than after an open operation [1].
Much attention has been paid to measures to reduce
the incidence and severity of renal insufficiency associ-
ated with CIN. A recent meta-analysis [7] investigating
multiple agents in this setting including N-acetylcysteine
(NAC), theophylline, furosemide, dopamine, bicarbonate,
iloprost and statins concluded that only NAC and theo-
phylline had a demonstrable benefit compared with hy-
dration alone, whereas furosemide had a detrimental
effect upon renal function. Within the setting of vascular
surgery the role of NAC is controversial [8–10] and not
universally utilised. The role of AA in CIN associated
with percutaneous cardiac interventions and radio-
graphic imaging, likely due to its antioxidant properties,
has been previously demonstrated to be beneficial in
high-risk patients [10, 11] however the evidence for its
routine use is again unclear [12, 13].
The mechanism of CIN is not well established but is
thought to be related to renal vasoconstriction and in-
creased osmotic load producing regional hypoxia, par-
ticularly in the renal medulla, which is susceptible to
hypoxia. Post-ischaemic oxidative changes lead to an in-
crease in production of free radical species, which in
turn produce renal damage [14, 15]. Therefore AA as an
anti-oxidant is thought to work in its role as a free rad-
ical scavenger.
Currently there is no data from either clinical or in
vivo models assessing the potential of AA as a nephro-
protective agent in patients undergoing endovascular
aneurysm repair. The aim of this study was to investigate
the role of AA in preventing CIN using an in vivo mur-
ine model. This was achieved using a variety of bio-
markers including NGAL, RBP-4, apoptosis (TUNEL
and Caspase 3) and karyolysis/inflammation (H&E stain-
ing) known or suspected to be associated with kidney
damage. The biomarkers were measured using different
assay formats (immunohistochemistry, ELISA, RT-PCR
and histopathology) in order to determine if pre-
treatment with AA has a potential therapeutic benefit in
preventing CIN.
Methods
Charles River UK performed in vivo studies in which
four groups of six BALB/c mice (weighing 6g each) were
injected with nitric oxide synthase inhibitors (NG -nitro-
L-arginine methyl ester, 10mg/kg) and an inhibitor of
prostaglandin synthesis (indomethacin 10mg/kg) intra-
peritoneally before Omnipaque administration (isohexol,
350mg iodine/ml, 1.5–3g iodine/kg). This is an estab-
lished model for generating reproducible renal failure
following radiocontrast injection [16]. Two groups were
then given either low (0.056g/kg) or high dose AA
(0.112g/kg) prior to contrast administration then after
12 and 24 h. The positive control group was given intra-
venous saline hydration 24 h post-administration of con-
trast media. The negative control group comprised no
administration of contrast media and received intraven-
ous saline hydration alone for the same time period.
Urine was collected and pooled from each group before
and after contrast injection, at 48 and 96 h then centri-
fuged and analysed for NGAL and creatinine. The
NGAL: creatinine ratio was then calculated. At the end
of the study kidneys from each mouse were explanted
and frozen at -80°C.
Histopathology
Standard histological techniques were used to fix and
embed one kidney, per mouse, in paraffin. Representa-
tive slices were stained with haematoxylin-eosin (HE)
and scored for damage to the tubules. The parameters
for scoring were karyolysis (scored in both the inner and
outer cortex) and inflammation (as scored by the pres-
ence of mononuclear cells in both the cortex and me-
dulla). Each parameter was scored from 0 to 4 with 0
representing no damage, 1 as mild, 2 as moderate, 3 as
severe and 4 as very severe/extensive.
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Immunohistochemistry and imaging
The explanted murine kidneys were frozen in liquid nitro-
gen and one kidney from each animal used for Caspase-3
and TUNEL (transferase mediated dUTP nick –end label-
ling). The tissue was cut to 10-μm sections on cryostat
and thaw mounted on SuperFrost slides (VWR, West Sus-
sex, UK). For both detection methods sections were fixed
in 2% paraformaldehyde (PFA) in 1x phosphate buffered
saline (PBS) for 10min and rehydrated in 1x PBS for
15min. For activated Caspase-3 staining only cell mem-
branes were permeabilised in PBS containing 0.5%
Tween-20 for 10min and washed 3x with 1x PBS + 0.05%
Tween-20 for 5 min each. The sections were blocked for
1h in blocking solution containing 2% BSA and 5% goat
serum in 1x PBS and washed 3x with 1x PBS for 5 min
each. All incubation steps were performed at room
temperature. Rabbit polyclonal anti-active Caspase-3 (p17
fragment) antibody (Abcam, Cambridge, UK) was diluted
1:100 in blocking solution and incubated with the sections
overnight at 4°C. After 3 washes in 1x PBS Alexa Fluor
488-labeled goat anti-rabbit secondary antibody (Invitro-
gen. Paisley, UK) was applied at 1:100 dilution in blocking
solution and incubated for 1h at room temperature in the
dark. After 3 washes in 1xPBS/0.05% Tween20 the sec-
tions were mounted with Vectashield medium containing
DAPI (Vector Laboratories, Peterborough, UK).
For TUNEL staining APO-BrdU™ TUNEL Assay Kit
(Invitrogen, Paisley, UK) was used and protocol adapted
for fluorescence microscopy. After fixation and rehydra-
tion as described above, sections were incubated in 70%
ice-cold ethanol at -20°C for 30 min. Ethanol was removed
and rinsed 3x with Wash Buffer. DNA-labelling solution
was prepared as per manufacturer instructions and ap-
plied on sections overnight at 4°C. After washing with
Rinse Buffer Alexa Fluor®488-labeled anti-BrdU mouse
monoclonal antibody was applied as per manufacturer in-
structions and incubated 1h at room temperature in the
dark. Sections were rinsed with PBS/0.05% Tween and
stained with propidium iodide/RNase A staining buffer for
1 h at room temperature in the dark. After 3 washes in
1xPBS/0.05% Tween20 the sections were mounted with
Vectashield medium containing DAPI (Vector Laborator-
ies, Peterborough, UK).
Confocal fluorescent images were acquired using Zeiss
LSM 510 Meta Confocal system (LSM software release
3.2) coupled to a Zeiss Axiovert 200 microscope. All im-
ages were acquired at room temperature.
mRNA analysis by quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was conducted on
the explanted mouse kidneys. Total RNA was extracted
from frozen tissue samples using PARIS™ Kit (Life Tech-
nologies – Invitrogen, Paisley, UK). First strand cDNA
synthesis was performed using QuantiTect Reverse
Transcription Kit (Qiagen, Manchester, UK) from 100ng
total RNA. All measurements were in duplicate and the
relative expression levels of lipocalin-2 (Lcn-2) and retinol
binding protein-4 (RBP-4) were each normalized
hypoxanthine-guanine phosphoribosyltransferase (HPRT),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
beta-2 microglobulin (B2M). qRT-PCR was performed on
a BioRad CFX96 Real time PCR machine using Quanti-
Tect SYBR Green PCR Master Mix (Qiagen, Manchester,
UK) and validated primer pairs Quantitact Primer Assay
(Qiagen, Manchester, UK) for all tested and housekeeping
genes. The PCR efficiency for each set of primers was pre-
viously established by analysing serial dilutions of cDNA.
Biochemical analysis of NGAL
NGAL was measured using a two-site time resolved fluor-
escence DELFIA immunoassay (PerkinElmer Inc, MA,
USA). Nunc Maxisorp plates (PerkinElmer Inc, MA, USA)
were coated overnight with a monoclonal anti-NGAL anti-
body (R&D Systems, MN, USA). After coating, the plates
were washed three times with DELFIA wash buffer and
blocked with 300μl of 1% BSA in PBS. Urine samples were
diluted 1 in 5 in DELFIA Multibuffer (PerkinElmer Inc,
MA, USA) before analysis. Standards were prepared from
recombinant murine NGAL (R&D Systems, MN, USA).
50μl standards, diluted urine or diluted QC samples were
added to the plate in duplicate followed by 100μl DELFIA
Multibuffer (PerkinElmer Inc, MA, USA). The plate was in-
cubated at room temperature for 2 h on a plate shaker. The
plate was then washed 4 times using an automated plate
washer and a biotinylated polyclonal anti-NGAL detection
antibody (R&D Systems, MN, USA) added to the wells.
The plate was then incubated at room temperature for a
further 2 h on a plate shaker. The plate was then washed 4
times using an automated plate washer and Europium la-
belled streptavidin (PerkinElmer Inc, MA, USA) added to
the wells. The plate was incubated at room temperature for
a further 40 min on a plate shaker. The plate was then
washed 6 times using an automated plate washer and 200μl
Enhancement solution (PerkinElmer Inc, MA, USA) added
to the wells. The plate was incubated for 10 min on a plate
shaker before time-resolved fluorescence readings were
taken on a Victor 3 plate reader (PerkinElmer Inc, MA,
USA). Results were calculated using the MultiCalc software
package (PerkinElmer Inc, MA, USA). The assay range was
78.1 pg/ml to 5000 pg/ml. Creatinine was measured using a
standard certified biochemistry assay (Department of
Biochemistry, Cambridge University NHS Trust).
For NGAL analysis from explanted kidney lysates, in-
dividual kidneys were ground in liquid nitrogen and
processed using a PARIS™ kit (Life Technologies – Invi-
trogen, Paisley, UK); half the sample was used for total
protein analysis. Total protein was estimated using a
Bradford assay (Thermo Scientific, Loughborough, UK)
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and each kidney sample was diluted to 20 μg protein/ml.
NGAL concentration was determined using a Human
Lipocalin-2/NGAL Quantikine ELISA Kit (R&D Sys-
tems, Abingdon, UK).
Statistics
Statistical analysis was undertaken using GraphPad
Prism v5 (GraphPad Software, La Jolla, CA). Binomial
data were analysed using contingency table analysis and
Fisher’s exact test used to calculate significance levels.
Continuous data was analysed with students’ t-test.
Significance was determined using 95% confidence (p <
0.05) in all cases.
Results
Urinary NGAL:creatinine ratio was significantly lower in
both the high and low dose AA groups when compared
to the positive control (saline hydration 24 h post-
contrast administration) group (Fig. 1). In the low dose
AA group there was a 44% reduction in mean NGAL:-
creatinine ratio at 48 h compared to the positive control
group (298.4μg/mmol versus 533.6μg/mmol, respect-
ively). The reduction in mean NGAL:creatinine urine ra-
tio appeared to persist at 96 h although this had reduced
to 34% compared to the positive control group. It was
apparent that there was a reasonably high degree of vari-
ability in the mean NGAL:creatinine ratios observed for
each group of mice and this was reflected by a lack of
significance at both time points for the low dose AA
group. A greater (62–58% reduction over 48–96 h time
period) and significant (p = 0.049) reduction in the mean
NGAL:creatinine ratio was however observed with the
high dose AA group at 96 h
Histopathology and immunohistochemistry
Explanted kidneys from the four groups of mice were
analysed by histology and immunohistochemistry for in-
flammatory and apoptotic markers. Histological analysis
of paraffin sections using haematoxylin and eosin stain-
ing of explanted kidneys revealed evidence of reduced
inflammation through mononuclear cell infiltration with
both the high dose and low dose AA treatments (Table 1
and Fig. 2). The positive control also showed higher
levels of karyohexis in the renal cortical tubular epithe-
lium compared to both AA treated groups, although
there was no difference between any of the groups in the
level of karyolysis (data not shown).
Immunohistochemical analysis of frozen kidney sec-
tions was performed by examining changes in the glom-
eruli and renal tubules of the explanted kidneys, where
treatment with contrast media is known to induce renal
cell apoptosis [17]. The TUNEL assay was used to deter-
mine the level of apoptosis and the results showed pro-
gressively lower levels of DNA nicking (TUNEL assay)
in the low and high dose AA groups compared to the
positive control group (Fig. 3). Further confirmation of
the TUNEL assay data was obtained by immunohisto-
chemical analysis for activated Caspase-3 expression.
Caspase-3 activation occurs upstream of DNA nicking,
thus early stages of induction of apoptotic signalling
could be determined by measuring activated Caspase-3
(using an antibody that specifically recognises the p17
fragment of the active enzyme) in the kidney sections.
Although Caspase-3 staining was relatively weak com-
pared to the TUNEL assay the results across the sections
were consistent with the results obtained in the TUNEL
assay, in that, a reduction in the Caspase-3 expression in
mice treated with AA was observed (Fig. 4). Importantly,
Caspase-3 expression appeared to correlate with the
dose of AA i.e. the high dose treatment resulted in the
largest reduction in Caspase-3 expression. Both the
histo- and immunohistochemical analysis of kidneys
from the AA treated mice showed a reduction in the
level of inflammation and a reduction in both early and
late stage apoptosis. Overall the reduction in inflamma-
tion and apoptosis appeared be greater with the high
dose AA treatment.
Biochemical analysis NGAL, Lcn-2 and RBP-4
Additional molecular and biochemical analysis of the
explanted kidneys in which biomarkers for NGAL, Lcn-
2 and RBP-4 was performed to determine the effect of
AA treatment on CIN. Kidney lysates were analysed by
NGAL-specific ELISA (Fig. 5) and the results showed
that treatment with AA significantly (p < 0.05) reduced
NGAL expression in the low dose AA group by 57%
compared to the positive control group (from 20,948 ng/
ml to 8,315ng/ml). The high dose AA group failed to
Fig. 1 Mean urinary NGAL:creatinine ratio (ug/ml) at 0 (baseline), 48
and 96 h following administration of contrast media between AA
treated groups (high and low dose AA). Significant (p < 0.05)
changes in NGAL:creatinine ratio are indicated (*) compared to the
positive control group
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show a reduction, however it was clear that ELISA data
from two mice (one in the high dose AA group and one
in the negative control) where extremely high resulting
in very large SD’s (indicated by data labels in Fig. 5).
Both data sets from both mice were considered errone-
ous and therefore excluded from subsequent analysis.
Removal of the two outliers in the data analysis reduced
the SD and resulted in a reduction in NGAL expression
in the high dose AA group of 22% compared to the posi-
tive control (from 20,948 ng/ml to 16,407 ng/ml) al-
though this was not significant (p = 0.4409).
To further elucidate whether the difference in high
and low dose NGAL expression was genuine qRT-PCR
analysis of Lcn-2 gene (encoding NGAL protein) mRNA
transcript expression in mRNA extracted from mouse
kidneys was performed (Fig. 6). A significant (p < 0.05)
decrease in Lcn-2 transcript was observed in the low
dose AA group compared to the positive control (16.75
fold expression vs. 3.69 fold expression relative to the
negative control group). However when comparing high
and low dose AA groups the high dose group had a
higher level of Lcn-2 transcript compared to the low
dose AA group (12.74 versus 3.69 fold expression rela-
tive to negative control, respectively). The level of Lcn-2
transcript was however still significantly lower in the
high dose AA group compared to the positive control.
Thus the results of the NGAL ELISA and Lcn-2 mRNA
data correlate and the unexpected finding that the greatest
reduction in NGAL expression was observed in the low
dose AA group was confirmed..In order to assess the in-
tegrity of the proximal renal tubule additional analysis by
qRT-PCR of RBP-4 transcript was performed (Fig. 6).
Measurement of RBP-4 in urine is arguably the most sen-
sitive biomarker for loss of function of the human prox-
imal renal tubule [18] although analysis of transcripts
from kidney mRNA extracts revealed no changes in the
levels of expression between the four groups.
Discussion
Contrast induced nephropathy is a predominant cause
of hospital acquired renal injury. There are an increasing
number of both diagnostic investigations and thera-
peutic procedures performed using radio-contrast. Fur-
thermore an ageing population, with a higher incidence
of underlying renal impairment, make it imperative that
greater attention is focused on the aetiology of CIN in
order to formulate effective prophylactic and therapeutic
strategies to reduce its incidence and associated morbid-
ity and mortality [19]. Contemporary evidence has
highlighted significantly higher mortality rates in pa-
tients who suffer acute kidney injury after emergency
aneurysm surgery at both 30-days and 12-months [20].
Clearly there is a clinical need for therapeutic strategies
aimed at prevention of CIN, and in this study we fo-
cused on investigating the potential of ascorbic acid in a
murine model.
An established [16] murine model was selected that
provides an effective model for CIN, and where a series
of biomarkers could be measured to determine the
Table 1 Histopathology (haematoxylin-eosin) scoring of
explanted kidneys for mononuclear inflammatory cell infiltration
from four groups at 400x magnification where the groups have
been scored: 0 = no damage, 1 =mild, 2 =moderate, 3 = severe
and 4 = very severe/extensive









































Fig. 2 Representative histopathological examination of paraffin embedded explanted kidneys using haematoxylin-eosin staining observed at
x400. a - Histology from positive control (group 3) showing karyolysis and karyorrhexis in the renal cortical tubular epithelium. The sections
showed a clear interstitial infiltrate of mononuclear cells (arrows). b - Histology from high dose AA treatment (group 2) demonstrating fewer infiltrating
mononuclear cells. Scale bar represents 50μm
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nephroprotective effect of high dose AA on renal tox-
icity. Key biomarkers, from urine and explanted kidneys,
selected for this study included NGAL (and the corre-
sponding Lcn-2 mRNA transcript), NGAL:creatinine ra-
tio (urine), apoptotic markers and kidney histology.
Overall, the results demonstrated compelling evidence
that in this murine model AA functions as a nephropro-
tective agent against CIN. These results add further
weight to the evidence from the percutaneous cardiology
setting [10, 12] that AA may be an agent, which could
be transferred to the endovascular setting to counteract
the influence of contrast media.
All the animals in this murine model had normal renal
function prior to contrast administration. We know that
in human studies patients with normal renal function
are at the lowest risk of developing CIN. Further work
in a murine model with pre-existing renal failure may
demonstrate greater benefits of AA. The risk of develop-
ing CIN is greatest in patients with pre-existing renal
impairment and diabetes. These patients are the most
likely to benefit from the use of a nephroprotective
agent. The risk of CIN in patients with normal renal
function is likely to increase with the increasing com-
plexity of endovascular interventions.
The low dose of AA trialled in this study was from a
clinical perspective considered a ‘mega-dose’ in that the
standard prophylactic daily dose quoted by the British
National Formulary is 25–75mg (with a therapeutic dose
of 250mg), therefore the high dose group should be
regarded a high ‘mega-dose’. No deleterious effects either
high or low dose AA were detected in this study, and both
doses conferred some level of nephroprotection against
CIN although in both the urinary NGAL:creatinine ratio
and apoptosis assays, the high dose AA group appeared to
be most resistant to CIN. Surprisingly, there have been no
human clinical trials investigating the use of such a high
dose AA in this setting, even used as a very short treat-
ment. There have been advocates for mega-dosing of AA,
particularly surrounding alternative medicine including
the treatment of the common cold and in cancer therapy.
The side effects from these doses (typically 2–4g daily) are
nausea, vomiting, diarrhoea and renal calculi. However
Fig. 3 TUNEL immunohistochemistry of kidney glomeruli. DNA nicking Brdu staining (green fluorescence and indicated by arrows) and DAPI
counterstained nuclei (red). Note the negative control showed high levels of non-specific staining indicated by white circles. Scale bar
represents 10μm
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previous research has suggested that high dose AA is safe;
Spargias et al. [10] used mega-doses of AA, administering
3g followed by 2g and 2g, and observed no negative side
effects in their study group. Our study design calculated
the low AA dose administered to the mice to be
Fig. 4 Caspase-3 immunohistochemistry of renal glomeruli and tubular cells. Activated caspase-3 (green fluorescence indicated by arrows) and
DAPI counterstained nuclei (blue). Scale bar represents 10μm
Fig. 5 NGAL ELISA of kidney lysates for individual mice. Dot plot
showing NGAL expression in individual mice (ng/ml) the mean
(horizontal lines) and range (SD) for all 6 mice in each group are
shown. Outliers (excluded from analysis) are indicated by red circles
and mean values represented by horizontal lines are for entire
group (red line) or for group excluding outlier data (black line). The
SD is calculated for all data including outliers
Fig. 6 Gene transcript analysis of Lcn-2 and RBP-4 by qRT-PCR
normalised to HPRT, GAPDH and B2M in the positive and negative
controls versus the two treatment arms. Data is shown as fold increase
above the negative control
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equivalent to the human dose utilised by Spargias et al
[10]. The dose of AA was based upon the standard human
dose per kilogram body weight, with the high dose repre-
senting twice this dose, however still remaining within the
previous documented megadosing regimens.
The most frequently quoted definition of CIN is an in-
crease in serum creatinine of 25–50% from baseline, gen-
erally occurring within 24 h of contrast administration.
With this in mind urine collection was performed at base-
line, 48 and 96 h followed by sacrifice of the mouse, in
order to maximise the observed level of renal damage fol-
lowing contrast administration. Serum creatinine however,
is relatively insensitive only rising out of the normal range
when 50% of the functioning renal mass is lost [19]. Fur-
thermore even modest changes in serum creatinine have a
strong association with in-hospital mortality [21]. Subclin-
ical markers of kidney injury, such as, NGAL, retinol
binding protein and albumin/creatinine ratios, not only
allow the identification of renal damage that is not nor-
mally identified by creatinine measurement alone, but also
they can potentially can identify the beneficial impact of
therapies aimed at mitigating the effects of radio-contrast
media. Furthermore, the evaluation of peri-operative renal
function and the impact of therapeutic strategies have
been hampered by the lack of sensitive and specific bio-
markers of acute kidney injury. We have previously shown
the value of retinol binding protein (RBP) as a reliable bio-
marker of CIN [8, 22]. In more contemporary work we
have also demonstrated the potential of NGAL to identify
early renal injury in patients undergoing endovascular
AAA repair [23]. In this study, the positive control data
from the murine model confirmed observations in previ-
ous studies [17, 24, 25] where it was demonstrated that
apoptosis triggered by CIN resulted in a higher frequency
of apoptotic cells in the glomerulus and renal tubules.
This supports the notion that at least one potential mech-
anism of CIN in patients may involve caspase-dependent
apoptosis, moreover administration of high dose AA ap-
pears to reduce apoptosis in the glomerulus.. There also
appears to be a dose-response relationship with regard the
effect of AA administration on apoptosis. One unexpected
finding was the fact that the low dose AA appeared to
have a more potent effect in reducing NGAL expression
(as both NGAL protein and Lcn-2 transcript) in the kid-
neys. There is no clear explanation for this result although
differences in the dose groups may be due to the kinetics
of NGAL induction (which were not investigated in this
study), thus the timing of the kidney removal after treat-
ment with contrast media may explain this finding. It is
clear that these preliminary observations offer potential
insights into the mechanisms of CIN and possible treat-
ments to ameliorate nephrotoxicity although further work
is required in both animal models and patients to under-
stand optimal dosing of AA and to investigate the effects
of AA in reducing oxidative stress in kidneys. One of the
limitation of this study is that biomarkers of oxidative
stress were not measured and this may have thrown fur-
ther light on the mechanism of action of ascorbic acid in
reducing CIN.
The concerns regarding CIN in EVAR patients are not
just related to the index procedure. There is increasing
evidence of long-term renal dysfunction that maybe re-
lated in part to further contrast administration during
surveillance CT imaging or at the time of subsequent
reinterventions. Measures to ameliorate CIN should be
taken during any subsequent contrast administration in
higher risk EVAR patients. There is now good contem-
porary data confirming that AA reduces the incidence of
CIN in patients undergoing coronary angiography by up
to a third [26]. One would anticipate that a similar bene-
fit would be observed in patients undergoing peripheral
vascular and aortic interventions. High dose AA appears
to be well tolerated in the coronary population and the
data presented in this study would support a clinical trial
of AA in patients undergoing non-coronary endovascu-
lar interventions.
Conclusion
In conclusion this study presents comprehensive basic
science evidence for the role of AA as a nephroprotec-
tive agent following contrast administration. Further
work is warranted to establish the role of this therapy in
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